Savant Capital LLC Decreases Stock Holdings in Illumina, Inc. $ILMN

Savant Capital LLC reduced its stake in shares of Illumina, Inc. (NASDAQ:ILMN) by 8.2% during the 2nd quarter, HoldingsChannel reports. The firm owned 62,370 shares of the life sciences company’s stock after selling 5,588 shares during the quarter. Savant Capital LLC’s holdings in Illumina were worth $5,951,000 at the end of the most recent reporting period.

A number of other large investors have also made changes to their positions in ILMN. Vanguard Group Inc. lifted its position in Illumina by 3.5% during the first quarter. Vanguard Group Inc. now owns 16,371,662 shares of the life sciences company’s stock worth $1,298,928,000 after buying an additional 558,243 shares in the last quarter. WCM Investment Management LLC raised its holdings in shares of Illumina by 5.9% during the 2nd quarter. WCM Investment Management LLC now owns 4,426,471 shares of the life sciences company’s stock worth $419,585,000 after acquiring an additional 247,460 shares during the period. Corvex Management LP boosted its position in shares of Illumina by 125.2% during the 1st quarter. Corvex Management LP now owns 3,829,608 shares of the life sciences company’s stock valued at $303,841,000 after acquiring an additional 2,129,449 shares during the last quarter. AQR Capital Management LLC boosted its position in shares of Illumina by 361.7% during the 1st quarter. AQR Capital Management LLC now owns 2,121,585 shares of the life sciences company’s stock valued at $165,484,000 after acquiring an additional 1,662,093 shares during the last quarter. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC grew its holdings in shares of Illumina by 51.7% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 1,960,385 shares of the life sciences company’s stock valued at $155,537,000 after purchasing an additional 667,978 shares during the period. 89.42% of the stock is currently owned by hedge funds and other institutional investors.

Illumina Stock Up 0.7%

Illumina stock opened at $121.90 on Friday. The company has a market capitalization of $18.63 billion, a PE ratio of 15.43, a price-to-earnings-growth ratio of 2.34 and a beta of 1.42. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.41 and a current ratio of 1.81. Illumina, Inc. has a fifty-two week low of $68.70 and a fifty-two week high of $154.43. The firm has a 50 day moving average price of $100.51 and a 200 day moving average price of $94.44.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Thursday, October 30th. The life sciences company reported $1.34 EPS for the quarter, topping analysts’ consensus estimates of $1.16 by $0.18. Illumina had a return on equity of 28.93% and a net margin of 29.36%.The company had revenue of $1.08 billion for the quarter, compared to analysts’ expectations of $1.07 billion. During the same period in the prior year, the firm earned $1.14 earnings per share. The firm’s revenue was up .4% compared to the same quarter last year. Illumina has set its FY 2025 guidance at 4.650-4.750 EPS. Research analysts expect that Illumina, Inc. will post 4.51 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities analysts have commented on the stock. TD Cowen lifted their target price on shares of Illumina from $110.00 to $115.00 and gave the stock a “hold” rating in a research note on Friday, October 31st. Stephens set a $110.00 price target on shares of Illumina and gave the company an “overweight” rating in a research report on Monday, August 4th. Evercore ISI upped their price objective on Illumina from $132.00 to $142.00 and gave the company an “outperform” rating in a report on Friday, October 31st. Wall Street Zen raised Illumina from a “hold” rating to a “buy” rating in a research note on Saturday. Finally, Barclays upped their price target on Illumina from $95.00 to $100.00 and gave the company an “underweight” rating in a research note on Friday, October 31st. Five analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company’s stock. Based on data from MarketBeat, Illumina presently has a consensus rating of “Hold” and an average price target of $115.00.

Insider Transactions at Illumina

In other news, Director Scott Gottlieb bought 500 shares of the firm’s stock in a transaction that occurred on Monday, November 3rd. The shares were purchased at an average price of $122.13 per share, with a total value of $61,065.00. Following the purchase, the director owned 12,523 shares in the company, valued at approximately $1,529,433.99. The trade was a 4.16% increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Insiders own 2.60% of the company’s stock.

Illumina Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.